PharmaShots Weekly Snapshots (May 31 – June 4, 2021)

 PharmaShots Weekly Snapshots (May 31 – June 4, 2021)

PharmaShots Weekly Snapshots (May 31 – June 4, 2021)

Tonix Pharmaceuticals Presents Results of TNX-102 SL in P-III RELIEF study for the Management of Fibromyalgia at ASCP 2021

Published: June 4, 2021 | Tags: Tonix Pharmaceuticals, TNX-102 SL, P-III, RELIEF Study, Fibromyalgia, ASCP 2021

Dermavant Submits NDA to the US FDA for Tapinarof Cream to Treat Plaque Psoriasis

Published: June 4, 2021 | Tags: Dermavant, NDA, US, FDA, Tapinarof Cream, Plaque Psoriasis

BMS Presents Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC at ASCO 2021

Published: June 4, 2021 | Tags: BMS, Opdivo, nivolumab, CT, Yervoy, ipilimumab, P-III, CheckMate -648 Trial, Unresectable, Advanced, Metastatic, ESCC, ASCO 2021

United Therapeutics Reports the First Patient Enrollment in P-III TETON Study of Tyvaso for Idiopathic Pulmonary Fibrosis

Published: June 4, 2021 | Tags: United Therapeutics, P-III, TETON Study, Tyvaso, Idiopathic Pulmonary Fibrosis

Merck Presents Results of Keytruda (pembrolizumab) in P-III KEYNOTE-564 as Adjuvant Therapy for Renal Cell Carcinoma at ASC0 2021

Published: June 4, 2021 | Tags: Merck, Keytruda, pembrolizumab, P-III, KEYNOTE-564, Renal Cell Carcinoma, ASC0 2021

Innovent and Lilly’s Tyvyt (sintilimab injection) + Gemcitabine and Platinum CT Receive NMPA’s Approval as 1L Therapy for Squamous Non-Small Cell Lung Cancer

Published: June 4, 2021 | Tags: Innovent, Lilly, Tyvyt, sintilimab injection, Gemcitabine, Platinum CT, NMPA, Approval, Squamous Non-Small Cell Lung Cancer

Biogen and Bio-Thera Report Results of BAT1806 (biosimilar, tocilizumab) in P-III Study for Moderate to Severe Rheumatoid Arthritis

Published: June 3, 2021 | Tags: Biogen, Bio-Thera, BAT1806, biosimilar, tocilizumab, P-III, Study, Rheumatoid Arthritis

Lupin Reports the US FDA Acceptance of BLA for Pegfilgrastim Biosimilar

Published: June 3, 2021 | Tags: Lupin, US, FDA, Acceptance, BLA, Pegfilgrastim Biosimilar

Celltrion Presents One Year Results of Yuflyma (biosimilar, adalimumab) in P-III CT-P17 3.1 Trial for Rheumatoid Arthritis at EULAR 2021

Published: June 3, 2021 | Tags: Celltrion, Yuflyma, biosimilar, adalimumab, P-III, CT-P17 3.1 Trial, Rheumatoid Arthritis, EULAR 2021

Novartis Presents Results of Kymriah in P-II ELARA Study for Relapsed or Refractory Follicular Lymphoma at ASCO 2021

Published: June 3, 2021 | Tags: Novartis, Kymriah, P-II, ELARA Study, Follicular Lymphoma, ASCO 2021

BMS’ Opdivo (nivolumab) + Yervoy (ipilimumab) Receive EC’s Approval for 1L Treatment for Unresectable Malignant Pleural Mesothelioma

Published: June 3, 2021 | Tags: BMS, Opdivo, nivolumab, Yervoy, ipilimumab, EC, Approval, Unresectable, Malignant Pleural Mesothelioma

MorphoSys to Acquire Constellation Pharmaceuticals for ~$1.7B

Published: June 3, 2021 | Tags: MorphoSys, Acquire, Constellation Pharmaceuticals, ~$1.7B

AbbVie Presents Results of Long-Term Efficacy and Safety Analyses for Rinvoq (upadacitinib) in P-III SELECT-COMPARE Study for Rheumatoid Arthritis at EULAR 2021

Published: June 2, 2021 | Tags: AbbVie, Rinvoq, upadacitinib, P-III, SELECT-COMPARE Study, Rheumatoid Arthritis, EULAR 2021

Novartis Presents Two-Year Data of Cosentyx in P-III JUNIPERA Study for JPsA and ERA at EULAR 2021

Published: June 2, 2021 | Tags: Novartis, Cosentyx, P-III, JUNIPERA Study, JPsA, ERA, EULAR 2021

AstraZeneca Presents Results of Anifrolumab in New Post-Hoc Analysis of P-III TULIP Study for Systemic Lupus Erythematosus at EULAR 2021

Published: June 2, 2021 | Tags: AstraZeneca, Anifrolumab, P-III, TULIP Study, Systemic Lupus Erythematosus, EULAR 2021

Alnylam Reports Completion of Patient Enrollment in P-III APOLLO-B Study for Patisiran to Treat Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy

Published: June 2, 2021 | Tags: Alnylam, P-III, APOLLO-B Study, Patisiran, Transthyretin-Mediated (ATTR) Amyloidosis, Cardiomyopathy

Janssen’s Teclistamab Receives the US FDA’s Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma

Published: June 2, 2021 | Tags: Janssen, Teclistamab, US, FDA, Breakthrough Therapy Designation, Multiple Myeloma

Novartis’ Cosentyx (secukinumab) Receives the US FDA’s Approval for the Treatment of Moderate to Severe Plaque Psoriasis

Published: June 2, 2021 | Tags: Novartis, Cosentyx, secukinumab, US, FDA, Approval, Moderate,  Severe, Plaque Psoriasis

Santhera and ReveraGen Report Results of Vamorolone in P-IIb VISION-DMD Study for Duchenne Muscular Dystrophy

Published: June 1, 2021 | Tags: Santhera, ReveraGen, Vamorolone, P-IIb, VISION-DMD Study, Duchenne Muscular Dystrophy

Amgen and Kyowa Kirin Collaborate to Develop and Commercialize KHK4083 for Atopic Dermatitis

Published: June 1, 2021 | Tags: Amgen, Kyowa Kirin, Develop, Commercialize, KHK4083, Atopic Dermatitis

Biohaven’s Nurtec ODT (rimegepant) Receives the US FDA’s Approval for Treatment of Migraine

Published: June 1, 2021 | Tags: Biohaven, Nurtec ODT, Rimegepant, US, FDA, Approval, Migraine

AB Science Holds the Clinical Studies of Masitinib Globally

Published: June 1, 2021 | Tags: AB Science, Holds, Clinical Studies, Masitinib

Sanofi Stops the P-II/III STAGED-PKD Study of Venglustat for Autosomal Dominant Polycystic Kidney Disease

Published: June 1, 2021 | Tags: Sanofi, P-II/III, STAGED-PKD Study, Venglustat, Autosomal Dominant Polycystic Kidney Disease

BMS’ Abecma (idecabtagene vicleucel) Receives the Health Canada’s Approval as the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma

Published: June 1, 2021 | Tags: BMS, Abecma, idecabtagene vicleucel, Health Canada, Approval, Anti-BCMA, CAR T Cell Therapy, Multiple Myeloma

Ipsen Reports the US FDA’s Acceptance of NDA for Palovarotene to Treat Fibrodysplasia Ossificans Progressiva

Published: May 31, 2021 | Tags: Ipsen, US, FDA, NDA, Palovarotene, Fibrodysplasia Ossificans Progressiva

Novo Nordisk Resubmits Label Expansion Application to the US FDA for Semaglutide (2.0mg)

Published: May 31, 2021 | Tags: Novo Nordisk, Resubmits, Label Expansion Application, US, FDA, Semaglutide (2.0mg)

BridgeBio and Helsinn’s Truseltiq (infigratinib) Receive the US FDA’s Approval for Cholangiocarcinoma

Published: May 31, 2021 | Tags: BridgeBio, Helsinn, Truseltiq, infigratinib, US, FDA, Approval, Cholangiocarcinoma

Novartis Reports One Year Results of Beovu (brolucizumabin) in P- III MERLIN Study to Treat Wet Age-Related Macular Degeneration

Published: May 31, 2021 | Tags: Novartis, Beovu, brolucizumabin, P- III, MERLIN Study, Wet Age-Related Macular Degeneration

Pfizer and BioNTech Receive EC’s Conditional Marketing Approval for the COVID-19 Vaccine in Adolescents

Published: May 31, 2021 | Tags: Pfizer, BioNTech, EC, Conditional Marketing Approval, COVID-19 Vaccine

Amgen’s Lumakras (sotorasib) Receives the US FDA’s Approval as the First KRAS Blocking Cancer Therapy

Published: May 31, 2021 | Tags: Amgen, Lumakras, sotorasib, US, FDA, Approval, KRAS Blocking Cancer Therapy

Related Post: PharmaShots Weekly Snapshots (May 24 – 28, 2021)

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post